NNNN Anbio Biotechnology Annual reports only
In Vitro & In Vivo Diagnostic Substances · Nasdaq · SEC CIK 1982708 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY5.6%
TTM net income YoY169.9%
TTM EPS YoY162.5%
Revenue 3-yr CAGR-28.4%
Net income 3-yr CAGR-13.8%
Margins
Gross margin87.2%
Operating margin66.7%
Net margin74.1%
FCF margin—
EBITDA margin—
Returns
ROE27.0%
ROA26.0%
ROIC (approx.)41.5%
Asset turnover0.35x
Leverage & solvency
Liabilities / assets0.3%
Debt / equity0.00x
Current ratio344.31x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-1.05x
Accruals ratio53.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $8.65M | $8.19M |
| Cost of revenue | $1.10M | $2.30M |
| Gross profit | $7.54M | $5.89M |
| R&D expense | $201,305 | $454,227 |
| SG&A expense | $1.57M | $3.44M |
| Operating income | $5.77M | $2.00M |
| Pretax income | $6.40M | $2.37M |
| Income tax | $0 | $0 |
| Net income | $6.40M | $2.37M |
| EPS (basic) | 0.15 | 0.06 |
| EPS (diluted) | 0.15 | 0.06 |
| Weighted avg. shares (diluted) | 43.67M | 42.29M |
| Balance sheet | ||
| Cash & equivalents | $7.77M | $11.76M |
| Short-term investments | $4.13M | $0 |
| Receivables | $3.66M | $1.06M |
| Current assets | $30.24M | $18.53M |
| Total assets | $30.24M | $18.92M |
| Current liabilities | $87,836 | $1.73M |
| Total liabilities | $87,836 | $1.73M |
| Shareholders' equity | $30.16M | $17.19M |
| Cash flow statement | ||
| Operating cash flow | -$6.74M | $2.08M |
| Investing cash flow | -$4.20M | $337,101 |
| Financing cash flow | $6.95M | -$344,605 |
Free plan shows the latest 2 periods; Pro shows all 4 🔒
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.